Molecular Dx Labs Fret Over Medicare Payment Setting, Or, In Some Cases, Lack Thereof
This article was originally published in The Gray Sheet
Executive Summary
The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.